are thought to have specific renoprotective effects in patients with diabetic and nondiabetic nephropathy. Some guidelines advocating the use of these drugs in renal disease, however, base their ...

Background: Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients ...